The word Oncotarget refers to all molecules, cellular functions and pathways common in microbes, cancer cells, neurons, lymphocytes, atherosclerosis, neurodegeneration, aging and cancer. Oncotarget is a free access journal and publishes weekly papers online. Every issue is available for printing on special demand. They strive to make scientific results widely and rapidly available in order to maximize the insightful reviews and impact of the research. Exceptional discoveries are quickly shared and fields of biomedical science are linked. This helps in the applications of clinical and basic science in regards to fighting disease. Oncotarget is led by prominent scientists and helps researchers with their contributions to science. Their goal is to have life without any disease. Visit classroomvoices.org to read more about Mikhail.
Mikhail Blagosklonny works at the Roswell Park Cancer Institute as a professor of Oncology. As a scientist he studies aging and cancer. He earned his MD in Internal Medicine at the First Pavlov State Medical University and also acquired his Ph.D. in Experimental Medicine and Cardiology. In 2002 he started working for the New York Medical College as an associate professor in the medical field. He eventually became the senior scientist at the Ordway Research Institute. In 2009 he made the move as the Professor of Oncology for the Roswell Park Cancer Institute. He has become an excellent professor due to the skills he has learned while working in different positions at numerous places. His interest in research includes anti-aging drugs, targeted therapies for cancer to guard healthy cells against damage and Biogerontology which is the study of the mechanisms that underlay aging.
Mikhail Blagosklonny works at Cell Cycle and Oncotarget as the editor in chief as well as being the associate editor for therapy and cancer biology. Mr. Blagosklonny has a place on the editorial board for Cell Death and Differentiation. He is responsible for the hypothesis for the TOR Signaling potential role in both aging and cancer. His proposal was to use Rapamycin, a popular drug currently used to treat cancer. He believes this treatment may be an option for life extension. Mikhail Blagosklonny has been named as one of the most passionate advocates regarding the use of Rapamycin regarding research into longevity. His research varies and includes clinical investigations and molecular and cellular biology. This generally includes mitosis, anticancer therapeutics, cell cycles, apoptosis, the resistance of normal cells drugs for selective protection, tumor suppressors, ontogenesis and signal transduction. Read more on templeofthecave.com
Mikhail Blagosklonny has written about an aging hyperfunction theory, chemotherapeutic engineering and cell cyclotherapy. His interest in oncology is passionate and believes it is possible to control both aging and cancer. He believes there is a cure for cancer and this was the basis for his suggestion regarding the use of Rapamycin. There are 300 reviews, book chapters and research articles published with his name. He is an associate editor for the International Journal of Cancer,PLOS ONE and the American Journal of Pathology. His commitment and hard work have helped him become one of the major oncology researchers worldwide. He believes he found his field because of his vision of a disease free world and his love for humanity.